BHST (BioHarvest Sciences, Inc.) Net Profit

Corporate emblem and logo of bioharvest.com (BHST)

BioHarvest Sciences (BHST) generates revenue from the sale of premium plant-based components for medicine and nutrition, utilizing a proprietary cell cultivation method. This trading chart captures the net profit dynamics, which reach -0.01. The company operates within the diversified pharmaceuticals sector, and its competitiveness is based on the BioFarming digital system, which radically reduces operating expenses in the production of bioactive compounds.

BHST (BioHarvest Sciences Inc.) Company Net Income history from 11/13/2024 to 10/31/2026

Financial and market metric breakdowns for BioHarvest Sciences Inc. (BHST)

- price and consensus price forecast:
Stock Quotes BioHarvest Sciences Inc|BHST - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization BioHarvest Sciences Inc|BHST - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share BioHarvest Sciences|BHST - Company Book Value|Market-to-Book Ratio bioharvest.com|BHST - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital BioHarvest Sciences|BHST - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital BioHarvest Sciences, Inc.|BHST - Company Aggregate Debts|Debts to Book Value BioHarvest Sciences Inc|BHST - Company Long-Term Debt|Company Short-Term Loans and Borrowings BioHarvest Sciences|Quick Liquidity bioharvest.com
- net income and valuation multiples indicators:
BHST - Net Profit
Fundamental valuation:BHST BioHarvest Sciences Inc
Flagship merchandise of BioHarvest Sciences, Inc.

BioHarvest Sciences (BHST) innovative cell-growth model using bioreactors directly impacts operational efficiency. This metric reflects the final remaining funds after deducting all operating and tax expenses from total revenue. By analyzing the company's net income, an investor assesses the business's actual ability to generate cash flow. This chart's dynamics allow for the differentiation of organic growth from speculative overheating. A steady increase in this metric confirms the sustainability of the issuer's technological leadership.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Net Profit TBPH (Theravance Biopharma, Inc.)|Aquestive Therapeutics Inc - Company Net Income|scPharma - Net Profit|Net Financial Result Tectonic Therapeutic, Inc. TECX|Tonix Pharmaceuticals (TNXP) - Company Net Income|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|EPRX (Eupraxia Pharmaceuticals, Inc.) - Net Profit|EXOZ: Final Profit|Net Profit ORMP|Net Profit enterabio.com (ENTX)|Company Net Income MindWalk Holdings HYFT|Final Profit ABVC|CPIX: Net Income|QNTM: Company Net Income|FGEN: Net Profit|Company Net Income Telomir Pharmaceuticals Corp (TELO)|Company Net Income Rani Therapeutics Holdings|Synergy CHC Corporation (SNYR) - Net Financial Result|Net Income RLYB (Rallybio Corporation)|Profit After Payment of Taxes LEXX|Pulmatrix Corp - Net Income|Final Profit PTHL|APM - Company Net Income|Net Financial Result lyratherapeutics.com LYRA|IBO: Net Profit|Net Income TNF Pharmaceuticals, Inc.|YCBD (cbdMD Inc.) - Net Profit|PainReform Corp (PRFX) - Net Financial Result|Net Profit CYTO|LIPO - Company Net Income|Company Net Income OptiNose OPTN|PIRS: Company Profit|Procaps Group SA - Net Profit|Petros Pharma (PTPI) - Net Income|QLI: Net Profit|Company Net Income acelyrin.com (SLRN)|Company Net Income TFF Pharmaceuticals, Inc.